Misplaced Pages

Dasatinib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 08:59, 31 October 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'UNII', 'KEGG').← Previous edit Latest revision as of 08:45, 4 November 2024 edit undoSpidermario (talk | contribs)Extended confirmed users670 edits Undid revision 1255318361 by 103.137.1.84 (talk): spamTag: Undo 
(180 intermediate revisions by 92 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}{{Use dmy dates|date=April 2020}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 407466945 | verifiedrevid = 458266659
| IUPAC_name = ''N''-(2-chloro-6-methylphenyl)-2-<nowiki>-2-methyl-4-pyrimidinyl]amino]-5-thiazole<br>carboxamide monohydrate | IUPAC_name = ''N''-(2-chloro-6-methylphenyl)-2-<nowiki>-2-methyl-4-pyrimidinyl]amino]-5-thiazole<br>carboxamide monohydrate
| image = Dasatinib.svg | image = Dasatinib.svg
| width = 325
| alt =
| image2 = Dasatinib-2GQG-ball-and-stick-flip.png
| width2 = 350
| alt2 =


<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename = Sprycel, Dasanix
| Drugs.com = {{drugs.com|monograph|dasatinib}} | Drugs.com = {{drugs.com|monograph|dasatinib}}
| MedlinePlus = a607063 | MedlinePlus = a607063
| licence_EU = Sprycel | licence_EU = yes
| DailyMedID = Dasatinib
| licence_US = Dasatinib | licence_US = Dasatinib
| pregnancy_AU = D | pregnancy_AU = D
| routes_of_administration = ] (])
| pregnancy_US = D
| ATC_prefix = L01
| ATC_suffix = EA02

| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Sprycel (Dasatinib) | website=] (TGA) | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02657-3 | format=PDF | access-date=18 July 2020}}</ref>
| legal_UK = POM
| legal_US = Rx-only | legal_US = Rx-only
| legal_EU = Rx-only
| routes_of_administration = Oral
| legal_EU_comment = <ref name="Sprycel EPAR" />
| legal_status = Rx-only


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = 96% | protein_bound = 96%
| metabolism = ] | metabolism = ]
| elimination_half-life = 1.3 to 5 hours | elimination_half-life = 1.3 to 5 hours
| excretion = Fecal (85%), ] (4%) | excretion = Fecal (85%), ] (4%)


<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}} | IUPHAR_ligand = 5678
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 302962-49-8 | CAS_number = 302962-49-8
| ATC_prefix = L01
| ATC_suffix = XE06
| PubChem = 3062316 | PubChem = 3062316
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01254 | DrugBank = DB01254
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2323020 | ChemSpiderID = 2323020
| UNII_Ref = {{fdacite|changed|FDA}} | UNII_Ref = {{fdacite|changed|FDA}}
| UNII = RBZ1571X5H | UNII = X78UG0A0RN
| KEGG_Ref = {{keggcite|changed|kegg}} | KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = <!-- blanked - oldvalue: D03658 --> | KEGG = D03658
| ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 49375 | ChEBI = 49375
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
Line 44: Line 59:
<!--Chemical data--> <!--Chemical data-->
| C=22 | H=26 | Cl=1 | N=7 | O=2 | S=1 | C=22 | H=26 | Cl=1 | N=7 | O=2 | S=1
| molecular_weight = 488.01 g/mol
| smiles = Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl | smiles = Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) | StdInChI = 1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}= {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZBNZXTGUTAYRHI-UHFFFAOYSA-N | StdInChIKey = ZBNZXTGUTAYRHI-UHFFFAOYSA-N
}} }}
'''Dasatinib''', previously known as '''BMS-354825''', is a cancer ] produced by ] and sold under the trade name '''Sprycel'''. Dasatinib is an oral multi- ] and ] family ] approved for use in patients with ] (CML) after ] treatment and ]-positive ] (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced ].


<!-- Definition and medical uses -->
The drug is named after one of the inventor chemists, ], who was a member of the large discovery and development team at Bristol Myers Squibb.<ref>{{cite journal | author = Das J ''et al.'' | title = 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-<nowiki>-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor | journal = J Med Chem | volume = 49 | issue = 23 | pages = 6819&ndash;32 | year = 2006 | pmid = 17154512 | doi = 10.1021/jm060727j}}
'''Dasatinib''', sold under the brand name '''Sprycel''' among others, is a ] medication used to treat certain cases of ] (CML) and ] (ALL).<ref name=AHFS2017>{{cite web|title=Dasatinib|url=https://www.drugs.com/monograph/dasatinib.html|publisher=The American Society of Health-System Pharmacists|access-date= 8 December 2017}}</ref> Specifically it is used to treat cases that are ]-positive (Ph+).<ref name=AHFS2017/> It is taken ].<ref name=AHFS2017/>
</ref>


<!-- Side effects and mechanism -->
==Origin and development==
Common ]s include ], ], ], ], rash, and diarrhea.<ref name=AHFS2017/> Severe adverse effects may include bleeding, ], ], and ].<ref name=AHFS2017/> Use during ] may result in harm to the baby.<ref name=AHFS2017/> It is a ] and works by blocking a number of ] such as ] and the ].<ref name=AHFS2017/>
{{empty section|date=October 2011}}


<!-- History and culture -->
==Efficacy==
Dasatinib was approved for medical use in the United States and in the European Union in 2006.<ref name=AHFS2017/><ref name="Sprycel EPAR">{{cite web | title=Sprycel EPAR | website=] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel | access-date=28 April 2020}} {{PD-notice}}</ref> It is on the ].<ref name="WHO21st">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref>
In a ] dose escalation study published in June 2006, dasatinib was tested in patients who were resistant to or who could not tolerate ].<ref name="pmid16775234">{{cite journal |author=Talpaz M, Shah NP, Kantarjian H, ''et al.'' |title=Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias |journal=N. Engl. J. Med. |volume=354 |issue=24 |pages=2531–41 |year=2006 |month=June |pmid=16775234 |doi=10.1056/NEJMoa055229 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16775234&promo=ONFLNS19}}</ref> Complete hematological responses<ref>Complete hematologic response was defined as normal ] and ] counts, no ] in the peripheral blood, <5% ]s plus ]s in the peripheral blood, <20% ] in the peripheral blood, and no extramedullary disease.</ref> were seen in 37 of 40 patients with chronic-phase CML. Major hematologic responses<ref>The definition of a major hematologic response was sufficiently abstruse that the reader is referred to the original article (Talpaz ''et al.'', 2006) for details.</ref> were seen in 31 of 44 patients with accelerated-phase CML, CML in blast crisis, or Ph+ ALL.


==Molecular targets== ==Medical uses==
Dasatinib is used to treat people with ] and people with ] who are positive for the ].<ref>{{cite journal | vauthors = Keating GM | title = Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia | journal = Drugs | volume = 77 | issue = 1 | pages = 85–96 | date = January 2017 | pmid = 28032244 | doi = 10.1007/s40265-016-0677-x | s2cid = 207489056 }}</ref>
) of ] (blue) in complex with dasatinib (red).]]
The main targets of dasatinib, are ], ], ], ]s, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2.


In the EU dasatinib is indicated for children with
==Duration of benefit==
* newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.<ref name="Sprycel EPAR" />
* newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.<ref name="Sprycel EPAR" />
* newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.<ref name="Sprycel EPAR" />


and adults with
Responses were maintained in 95% of patients with chronic-phase CML, with a median follow-up time of >12 months. In patients with accelerated-phase CML, 82% remained in remission, although with a median follow-up of only 5 months. Nearly all patients with CML in blast crisis or Ph+ ALL relapsed within 6 months.
* newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;<ref name="Sprycel EPAR" />
* chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;<ref name="Sprycel EPAR" />
* Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.<ref name="Sprycel EPAR" />


== Adverse effects==
==Susceptible genotypes==
The most common side effects are ], ] (decreasing numbers of ]s, ]s, and ]s),<ref name="pmid17591830">{{cite journal | vauthors = Olivieri A, Manzione L | title = Dasatinib: a new step in molecular target therapy | journal = Annals of Oncology | volume = 18 | issue = Suppl 6 | pages = vi42–vi46 | date = June 2007 | pmid = 17591830 | doi = 10.1093/annonc/mdm223 | doi-access = free }}</ref> ], hemorrhage (bleeding), ] (fluid around the lungs), ] (difficulty breathing), ], ], ] (feeling sick), ] (belly ache), ], ], ], ], ].<ref name="Sprycel EPAR" /> ] and ] were common toxic effects. Fifteen people (of 84, i.e. 18%) in the above-mentioned study developed ]s, which was a suspected side effect of dasatinib. Some of these people required ] or ] to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral ], and ]. A small number of people developed abnormal ] which returned to normal without dose adjustments. Mild ] was also noted, but did not appear to cause any significant problems. Several cases of ] (PAH) were found in people treated with dasatinib,<ref>{{cite web|url=http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/|title=NHS - Healthcare News|website=nelm.nhs.uk|access-date=2011-09-27|archive-url=https://archive.today/20130505141147/http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/|archive-date=2013-05-05|url-status=dead}}</ref> possibly due to pulmonary ] damage.<ref name="pmid29334406">{{cite journal | vauthors=Yurttaş NO, Eşkazan AE | title=Dasatinib-induced pulmonary arterial hypertension | journal=] | volume=84 | issue=5 | pages=835–845 | year=2018 | pmc =5903230 |doi = 10.1111/bcp.13508 | pmid=29334406}}</ref>
Responses were seen in patients with all ] genotypes, with the exception of T315I mutation, which confers resistance to both dasatinib, nilotinib and ] ''in vitro''.


On October 11, 2011, the U.S. ] (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (], PAH).<ref name="FDA 20111011">{{cite web | title=Sprycel (dasatinib) and risk of pulmonary arterial hypertension | website=U.S. ] (FDA) | date=23 September 2011 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-sprycel-dasatinib-and-risk-pulmonary-arterial-hypertension | access-date=28 April 2020}} {{PD-notice}}</ref> Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs).<ref name="FDA 20111011" /> In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment.<ref name="FDA 20111011" /> Information about the risk was added to the Warnings and Precautions section of the Sprycel drug label.<ref name="FDA 20111011" /> In studies between 2009 and 2017 dasatinib-induced PAH was initiated between 0.3 and 74 months of daily drug usage at doses from 70 to 140&nbsp;mg.<ref name="Özgür Yurttaş Eşkazan 2018 pp. 835–845">{{cite journal | vauthors = Özgür Yurttaş N, Eşkazan AE | title = Dasatinib-induced pulmonary arterial hypertension | journal = British Journal of Clinical Pharmacology | volume = 84 | issue = 5 | pages = 835–845 | date = May 2018 | pmid = 29334406 | pmc = 5903230 | doi = 10.1111/bcp.13508 | publisher = Wiley }}</ref> Reported dasatinib-induced PAH had improvements after cessation of drug treatment.<ref name="Özgür Yurttaş Eşkazan 2018 pp. 835–845"/>
==Toxicities==
] and ] were common toxic effects. Fifteen patients (of 84, ie 18%) in the above-mentioned study developed ]s, which were felt to be a side effect of dasatinib. Some of these patients required ] or ] to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral ], and ]. A small number of patients developed abnormal ] which returned to normal without dose adjustments. Mild ] was also noted, but did not appear to cause any significant problems.Several cases of ] (PAH) were found in patients treated with dasatinib.<ref></ref>


==Pharmacology==
== Adverse effects==
) of ] (blue) in complex with dasatinib (red).]]
On October 11, 2011 the U.S. ] (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (], PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting dasatinib, including after more than one year of treatment.
Dasatinib is an ATP-competitive protein ]. The main targets of dasatinib are ] (the "Philadelphia chromosome"), ], ], ]s, and several other tyrosine kinases.<ref name="pmid32664269">{{cite journal | vauthors=Piscitani L, Sirolli V, Morroni M, Bonomini M | title=Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations | journal= ]| volume=21 | issue=14 | pages=e4878 | year=2020 | doi = 10.3390/ijms21144878 | pmid=32664269| pmc=7402330 | doi-access=free }}</ref> Strong inhibition of the activated BCR-ABL kinase distinguishes dasatinib from other CML treatments, such as ] and ].<ref name="pmid32664269" /><ref name="pmid32289275">{{cite journal | vauthors=Braun TP, Eide CA, Druker BJ| title=Response and Resistance to BCR-ABL1-Targeted Therapies | journal= ]| volume=37 | issue=4 | pages=530–542| year=2020 | doi = 10.1016/j.ccell.2020.03.006 | pmid=32289275| pmc=7722523 }}</ref> Although dasatinib only has a ] of three to five hours, the strong binding to BCR-ABL1 results in a longer duration of action.<ref name="pmid32289275" />


==History==
And information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.<ref>FDA: , 10/11/2011.</ref>
{{see also|Discovery and development of Bcr-Abl tyrosine kinase inhibitors}}
Dasatinib was developed by collaboration of ] and Otsuka Pharmaceutical Co., Ltd,<ref>{{cite web | title = Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area | date = 17 April 2023| url = https://www.otsuka.co.jp/en/company/release/2015/0302_01.html}}</ref><ref>{{cite press release | title = FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase | url = https://news.bms.com/news/r-and-d/2013/FDA-Approves-US-Product-Labeling-Update-for-Sprycel-dasatinib-to-Include-Three-Year-First-Line-and-Five-Year-Second-Line-Efficacy-and-Safety-Data-in-Chronic-Myeloid-Leukemia-in-Chronic-Phase/default.aspx| work = Bristol-Myers Squibb | access-date = 23 April 2015 | archive-date = 20 September 2018 | archive-url = https://web.archive.org/web/20180920151146/https://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f | url-status = dead }}</ref><ref>{{cite press release | title = Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology Collaboration with Otsuka | url = https://news.bms.com/news/corporate-financial/2009/Bristol-Myers-Squibb-Announces-Extension-of-US-Agreement-for-ABILIFY-and-Establishment-of-an-Oncology-Collaboration-with-Otsuka/default.aspx| archive-url = https://web.archive.org/web/20150131004436/http://news.bms.com/press-release/financial-news/bristol-myers-squibb-announces-extension-us-agreement-abilify-and-estab | url-status = dead | archive-date = 31 January 2015 | work = Bristol-Myers Squibb }}</ref> and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the ]s' underlying assumptions at a time when progress in the development of the molecule had stalled.<ref name="Drahl2012">{{cite web |vauthors=Drahl C |title=How Jagabandhu Das made dasatinib possible |url=http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/ |website=The Safety Zone blog |publisher=] |access-date=29 August 2016 |date=16 January 2012 |archive-date=10 December 2017 |archive-url=https://web.archive.org/web/20171210232159/http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/ |url-status=dead }}</ref>


== Society and culture==
==See also==
=== Legal status ===
*]
Dasatinib was approved for used in the United States in June 2006 and in the European Union in November 2006<ref>{{cite web | title=Drug Approval Package: Sprycel (Dasatinib) NDA #021986 & 022072 | website=U.S. ] (FDA) | date=6 September 2006 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986_022072_SprycelTOC.cfm | access-date=28 April 2020}}</ref><ref name="Sprycel EPAR" />


In October 2010, dasatinib was approved in the United States for the treatment of newly diagnosed adults with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (CP-CML).<ref>{{cite web | title=2010 Notifications | website=U.S. ] (FDA) | date=18 November 2010 | url=https://www.fda.gov/drugs/resources-information-approved-drugs/2010-notifications | access-date=28 April 2020}} {{PD-notice}}</ref>
==References==
{{reflist|2}}


In November 2017, dasatinib was approved in the United States for the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.<ref name="FDA PR 20171109">{{cite web | title=FDA approves dasatinib for pediatric patients with CML | website=U.S. ] (FDA) | date=9 November 2017 | url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dasatinib-pediatric-patients-cml | access-date=28 April 2020}} {{PD-notice}}</ref>
==External links==
*
*
* (from the European Medicines Agency website)


Approval was based on data from 97 pediatric participants with chronic phase CML evaluated in two trials—a Phase I, open-label, non-randomized, dose-ranging trial and a Phase II, open-label, non-randomized trial.<ref name="FDA PR 20171109" /> Fifty-one participants exclusively from the Phase II trial were newly diagnosed with chronic phase CML and 46 participants (17 from the Phase I trial and 29 from the Phase II trial) were resistant or intolerant to previous treatment with imatinib.<ref name="FDA PR 20171109" /> The majority of participants were treated with dasatinib tablets 60&nbsp;mg/m<sup>2</sup> ] once daily.<ref name="FDA PR 20171109" /> Participants were treated until disease progression or unacceptable toxicity.<ref name="FDA PR 20171109" />
{{Extracellular chemotherapeutic agents}}

===Economics===
The Union for Affordable Cancer Treatment objected to the price of dasatinib, in a letter to the U.S. trade representative. The average wholesale price in the U.S. is $367 per day, twice the price in other high income countries. The price in India, where the average annual per capita income is $1,570, and where most people pay out of pocket, is Rs6627 ($108) a day. Indian manufacturers offered to supply generic versions for $4 a day, but, under pressure from the U.S., the Indian Department of Industrial Policy and Promotion refused to issue a compulsory license.<ref name=Cost2014>{{cite journal | vauthors = Cohen D | title = US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says | journal = BMJ | volume = 349 | pages = g6593 | date = November 2014 | pmid = 25370846 | doi = 10.1136/bmj.g6593 | s2cid = 206903723 }}</ref>

Bristol-Myers Squibb justified the high prices of cancer drugs with the high R&D costs, but the Union of Affordable Cancer Treatment said that most of the R&D costs came from the U.S. government, including National Institutes of Health funded research and clinical trials, and a 50% tax credit. In England and Wales, the National Institute for Health and Care Excellence recommended against dasatinib because of the high cost-benefit ratio.<ref name=Cost2014/>

The Union for Affordable Cancer Treatment said that "the dasatinib dispute illustrates the shortcomings of US trade policy and its impact on cancer patients"<ref name=Cost2014/>

===Brand names===
In ] dasatinib is available under the trade name Dasanix by ].<ref>{{Cite web |title=Dasanix |url=https://medex.com.bd/brands/27272/dasanix-50mg |publisher=Medex |access-date=19 May 2021}}</ref> In India, It is marketed under the brand name Nextki by Emcure Pharmaceuticals.{{medcn|date=April 2020}}

==Research==

Dasatinib has been shown to eliminate ] in cultured ].<ref name="pmid32686219" />

===Dasatinib+Quercetin===

Dasatinib has been shown to induce apoptosis in senescent cells by ], whereas ] inhibits the anti-apoptotic protein ].<ref name="pmid32686219">{{cite journal | vauthors=Kirkland JL, Tchkonia T | title=Senolytic drugs: from discovery to translation | journal=] | year=2020 | volume=288 | issue=5 | pages=518–536 | doi = 10.1111/joim.13141 | pmc=7405395 | pmid=32686219}}</ref> Administration of dasatinib along with quercetin to mice improved ] function and eliminated senescent cells.<ref name="pmid31746100">{{cite journal | vauthors=Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D | title=Targeting senescent cells in translational medicine | journal=] | volume=11 | issue=12 | pages=e10234 | year=2019 | doi = 10.15252/emmm.201810234 | pmc=6895604 | pmid=31746100}}</ref> Aged mice given dasatinib with quercetin showed improved health and survival.<ref name="pmid31746100" />

A study of fourteen human patients with ] (a disease characterized by increased numbers of senescent cells) given dasatinib and quercetin showed improved physical function and evidence of reduced senescent cells.<ref name="pmid32686219" />

== References ==
{{reflist}}

== Further reading ==
{{refbegin}}
* {{cite journal | vauthors = Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM | display-authors = 6 | title = Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays | journal = Journal of Medicinal Chemistry | volume = 47 | issue = 27 | pages = 6658–61 | date = December 2004 | pmid = 15615512 | doi = 10.1021/jm049486a }}
{{refend}}

== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/rn/302962-49-8 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Dasatinib }}

{{Targeted cancer therapeutic agents}}
{{Growth factor receptor modulators}}
{{Piperazines}} {{Piperazines}}
{{Portal bar|Medicine}}


]
]
]
]
]
] ]
] ]
]
]
] ]
] ]
] ]
]
]
]
]
]

]
]
]
]
]
]
]